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MiR-103a-3p targets the 5′ UTR of GPRC5A
in pancreatic cells
HONGLEI ZHOU and ISIDORE RIGOUTSOS
Computational Medicine Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
ABSTRACT
MicroRNAs (miRNAs) are short noncoding RNAs that regulate the expression of their targets in a sequence-dependent manner. For
protein-coding transcripts, miRNAs regulate expression levels through binding sites in either the 3′ untranslated region (3′ UTR) or
the amino acid coding sequence (CDS) of the targeted messenger RNA (mRNA). Currently, for the 5′ untranslated region (5′ UTR)
of mRNAs, very few naturally occurring examples exist whereby the targeting miRNA down-regulates the expression of the
corresponding mRNA in a seed-dependent manner. Here we describe and characterize two miR-103a-3p target sites in the 5′
UTR of GPRC5A, a gene that acts as a tumor suppressor in some cancer contexts and as an ongocene in other cancer contexts.
In particular, we show that the interaction of miR-103a-3p with each of these two 5′ UTR targets reduces the expression levels
of both GPRC5A mRNA and GPRC5A protein in one normal epithelial and two pancreatic cancer cell lines. By ectopically
expressing “sponges” that contain instances of the wild-type 5′ UTR targets we also show that we can reduce miR-103a-3p
levels and increase GPRC5A mRNA and protein levels. These findings provide some first knowledge on the post-transcriptional
regulation of this tumor suppressor/oncogene and present additional evidence for the participation of 5′ UTRs in miRNA
driven post-transcriptional regulatory control.
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INTRODUCTION
MiRNAs comprise a group of short noncoding RNAs that
post-transcriptionally regulate gene expression in multi-
cellular organisms in a sequence-dependent manner (Bartel
2004). The “seed” region of a miRNA, defined as the seq-
uence spanning bases 2 through 7 inclusive from the 5′ end
of the miRNA, determines a miRNA’s spectrum of targets
(Miranda et al. 2006; Bartel 2009; Rigoutsos and Tsirigos
2010; Xia et al. 2012). So far, more than 17,000 mature
miRNA sequences from 140 different species have been iden-
tified (Kozomara and Griffiths-Jones 2011). With regard to
target cardinality, a single miRNA can simultaneously target
multiple mRNAs, thusly decreasing, to varying degrees, the
abundance of the corresponding protein (Miranda et al.
2006; Baek et al. 2008; Selbach et al. 2008).
MiRNA research began more than 20 years ago (Lee et al.
1993; Wightman et al. 1993; Hamilton and Baulcombe 1999;
Reinhart et al. 2000) and efforts since then have revealed that
the identification of miRNA targets is an inherently diffi-
cult problem (Rigoutsos and Tsirigos 2010). Nonetheless,
the field has made great advances during this time and nu-
merous miRNA targets have been described in the literature
to date with the majority of these targets being located in
the 3′ UTR of the targeted mRNAs (Bartel 2009). In recent
years, others and we have shown that miRNAs can also tar-
get mRNAs within their CDS and decrease the corresponding
protein’s abundance (Duursma et al. 2008; Forman et al.
2008; Lal et al. 2008; Shen et al. 2008; Tay et al. 2008;
Rigoutsos 2009; Brest et al. 2011; Hao et al. 2011; Nelson
et al. 2011; Sauna and Kimchi-Sarfaty 2011; Gartner et al.
2013; Hausser et al. 2013; Radhakrishnan et al. 2013; Shaba-
lina et al. 2013).
In contrast, identifying targets in the 5′ UTR of mRNAs
has proven more difficult. In early work, use of artificial con-
structs containing multiple copies of known miRNA targets
showed that from a mechanistic standpoint miRNAs can
repress mRNAs through 5′ UTR binding just as efficiently
as through 3′ UTR binding (Lytle et al. 2007; Devlin et al.
2010; Moretti et al. 2010). For naturally occurring targets,
two subsequent studies reported examples whereby 5′ UTR
targeting by the miRNA did not down-regulate the mRNA
but instead enhanced protein translation and increased pro-
tein levels (Henke et al. 2008; Orom et al. 2008; Tsai et al.
2009; Da Sacco and Masotti 2012). Four subsequent reports
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described a few examples of 5′ UTR binding sites that led to
the down-regulation of the targeted transcript (Jopling et al.
2005; Lee et al. 2009; Grey et al. 2010; Dewing et al. 2012).
More recently, a C. elegans study discussed the possibility of
a miRNA target in the 5′ UTR of CBP-1’s mRNA (Vora
et al. 2013).
Below, we report on our validation of two human miR-
103a-3p targets in the 5′ UTR of the human GPRC5A gene
(ENSG00000013588/ENST00000014914). GPRC5A encodes
an orphan G-protein-coupled receptor that was originally
reported to be overexpressed in normal lung tissue and
underexpressed in lung cancer; since then, GPRC5A’s dysre-
gulation has been associated with multiple cancer types: In
some cancers, GPRC5A can act as a tumor suppressor where-
as in others it can act as an oncogene (Tao et al. 2007; Acqua-
freda et al. 2009; Cheng et al. 2012). MiR-103a-3p is a notable
miRNA in that it is evolutionarily conserved and involved
in regulating multiple cellular processes such as cell division,
cellular metabolism and stress, angiogenesis, etc. (Finnerty
et al. 2010). MiR-103a-3p’s dysregulation has been associ-
ated with many human diseases including several cancers,
Alzheimer’s disease, and diabetes (Martello et al. 2010; Yao
et al. 2010; Trajkovski et al. 2011).
RESULTS
We studied the interactions of miR-103a-3p and GPRC5A,
both of which are endogenous to pancreatic cell lines and tis-
sue (both normal and cancer). We focused on two candidate
miR-103a-3p targets in the 5′ UTR of GPRC5A. The first pu-
tative miR-103a-3p MRE (site S11) is located between nucle-
otides 117 and 140 inclusive, whereas the second putative
MRE (site S12) is located between nucleotides 330 and 353
inclusive (Fig. 1A).
Increase in miR-103a-3p abundance reduces both
GPRC5A mRNA and protein levels
We transiently transfected MIA PaCa-2 cells with Pre-miR-
103a-3p or Anti-miR-103a-3p at a concentration of 50 nM
for 48 h. MIA PaCa-2 Cells transfected with only a scram-
bled sequence, either Pre-miR-scramble or Anti-miR-scram-
ble, were examined in parallel as controls. Transfection
with Pre-miR-103a-3p enhanced the expression of mature
miR-103a-3p 900 ± 132-fold (P < 0.001)—see Supplemental
Figure 1A—whereas transfection with Anti-miR-103a-3p re-
duced the expression of mature miR-103a-3p 11.9 ± 2.6-fold
(P < 0.001)—see Supplemental Figure 1B. In comparison to
Pre-miR-scramble, transfection of MIA PaCa-2 cells with
Pre-miR-103a-3p resulted in a 30% (P < 0.001) decrease of
GPRC5A mRNA (Fig. 1B). Notably, the decrease in protein
levels (50%, P < 0.01) was much higher than the decrease
of mRNA levels (Fig. 1D). In addition, transfection of MIA
PaCa-2 cells with Anti-miR-103a-3p resulted in up-regula-
tion of GPRC5A mRNA and an increase in GPRC5A protein
levels, compared with Anti-miR-scramble treatment group
(Fig. 1C,E).
MiR-103a-3p directly interacts with both S11
and S12 in the 5′ UTR of GPRC5A
We constructed separate reporter expression vectors con-
taining the wild-type (WT) or mutant (MT) binding sites,
in turn placing them downstream (S11WT-3′Luc, S12WT-
3′Luc, S11MT-3′Luc, and S12MT-3′Luc) from and upstream
(S11WT-5′Luc, S12WT-5′Luc, S11MT-5′Luc, and S12MT-
5′Luc) of the luciferase gene (Fig. 2A; Supplemental Fig.
2A). MIA PaCa-2 cells were cotransfected with Pre-miR-
scramble or Pre-miR-103a-3p and a reporter expression vec-
tor containing wild-type or mutant binding site, respectively.
The S11 site was more responsive to miR-103a-3p treatment
than the S12 site: Indeed, pre-miR-103a-3p reduced lu-
ciferase activity by 27% ± 6% (P < 0.01) in cells transfected
with S11WT-3′Luc and 17% ± 4% (P < 0.05) in cells trans-
fected with S12WT-3′Luc (Fig. 2B; Supplemental Fig. 2B).
Repeating the experiments with the 5′ luciferase constructs
gave similar results: In cells transfected with S11WT-5′Luc
pre-miR-103a-3p reduced luciferase activity by 24% ± 6%
(P < 0.01), whereas the reduction was 17% ± 4% (P < 0.05)
in cells transfected with S12WT-5′Luc (Fig. 2D; Supplemen-
tal Fig. 2D). Introduction of disruptive mutations in each of
the two miR-103a-3p sites rescued the inhibitory effect of
Pre-miR-103a-3p on luciferase activity and for both the 5′
and the 3′ luciferase constructs (Fig. 2B,D; Supplemental
Fig. 2B,D). MIA PaCa-2 cells were also cotransfected with
Anti-miR-scramble or Anti-miR-103a-3p and a reporter ex-
pression vector containing the WT or MT binding site (sep-
arately for the 5′ and 3′ luciferase constructs). Transfection
with Anti-miR-103a-3p increased luciferase activity by
45% ± 18% (P < 0.05) and 18% ± 12% (P = 0.06) in cells
transfected with S11WT-3′Luc and S12WT-3′Luc, respec-
tively (Fig. 2C; Supplemental Fig. 2C) and by 17% ± 3% (P
< 0.01) and 30% ± 6% (P < 0.001) in cells transfected with
S11WT-5′Luc and S12WT-5′Luc, respectively (Fig. 2E;
Supplemental Fig. 2E). Notably, for each of the two sites
S11 and S12, the observed increase in luciferase activity in
the presence of anti-miR-103a-3p was concordant with the
decrease of luciferase activity in the presence of miR-103a-
3p; i.e., the S11 site was more responsive to miR-103a-3p/
anti-miR-103a-3p than the S12 site. Lastly, mutations in
the two miR-103a-3p sites impaired the induction effect of
Anti-miR-103a-3p on luciferase activity (Fig. 2C; Supple-
mental Fig. 2C).
MiR-103a-3p targeting of the 5′ UTR of GPRC5A
mRNA decreases GPRC5A protein levels
Wenext sought to determine whether the interaction of miR-
103a-3p with the 5′ UTR of GPRC5A affected GPRC5A pro-
tein levels. To this end, we constructed two expression
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vectors. The first vector, labeled GPRC5A-5′UTR-CDS, con-
tained GPRC5A’s wild-type 5′ UTR and CDS regions only
(Supplemental Fig. 3A,B); i.e., the vector lacked GPRC5A’s
3′ UTR. The second vector, labeled GPRC5A-CDS, lacked
both untranslated regions and comprised only GPRC5A’s
wild-type CDS region (Supplemental Fig. 3C). We cotrans-
fected MIA PaCa-2 cells with a control vector containing
GFP open frame region (ORF), Pre-miR-scramble or Pre-
FIGURE 1. MiR-103a-3p abundance affects both GPRC5A mRNA and protein levels. (A) Analysis using the rna22 algorithm suggests two putative
miR-103a-3p binding sites, S11 and S12, respectively, in the 5′ UTR. (B) Ectopic overexpression of miR-103a-3p inMIA PaCa-2 cells reducesGPRC5A
mRNA levels. (C) Ectopic overexpression of anti-miR-103a-3p in MIA PaCa-2 cells increases GPRC5AmRNA levels. (D) Ectopic expression of miR-
103a-3p reduces GPRC5A protein expression. (E) Overexpression of miR-103a-3p inhibitors increases GPRC5A protein expression. (F)
Quantification result of D. (G) Quantification result of E. All numerical data are mean ± SD. (∗∗) P < 0.01; (∗∗∗) P < 0.001, n = 3. GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase, GAPDH and Actin are internal controls.
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miR-103a-3p, and either the GPRC5A-5′UTR-CDS or the
GPRC5A-CDS expression vector. Pre-miR-103a-3p reduced
GPRC5A expression in cells transfected with the GPRC5A-
5′UTR-CDS vector but did not have an inhibitory effect on
the GPRC5A-CDS vector (Fig. 3A). This demonstrated that
miR-103a-3p down-regulates GPRC5A protein by binding
to the 5′ UTR of GPRC5A’s mRNA.
Overexpression of the 5′ UTR MRE can increase
GPRC5A mRNA and protein levels
To further corroborate the targeting of GPRC5A’s 5′ UTR by
miR-103a-3p we made use of the concept of “sponging” or
“decoying” (Ebert and Sharp 2010a,b; Poliseno et al. 2010;
Tay et al. 2011), which was recently demonstrated to be able
FIGURE 2. MiR-103a-3p directly targets two sites in the 5′ UTR of GPRC5A. (A) The scheme indicates the sequences of the predicted miR-103a-3p
binding sites (S11) within the 5′ UTR of GPRC5A and the sequences of S11 wild-type (WT, top) and mutant (MT, bottom) used in this study.
(B) Luciferase activity in MIA PaCa-2 cells upon transfection of indicated reporter constructs and pre-miR-103a-3p were compared with cells trans-
fected with indicated reporter constructs and pre-miR-scramble. (C) Luciferase activity in MIA PaCa-2 cells upon transfection of indicated reporter
constructs andmiR-103a-3p inhibitors was compared with cells transfected with indicated reporter constructs and Anti-miR-scramble. (D) Luciferase
activity in MIA PaCa-2 cells upon transfection of indicated reporter constructs and pre-miR-103a-3p were compared with cells transfected with the
indicated reporter constructs and pre-miR-scramble. (E) Luciferase activity inMIA PaCa-2 cells upon transfection of the indicated reporter constructs
and miR-103a-3p inhibitors was compared with cells transfected with the indicated reporter constructs and Anti-miR-scramble. All numerical data
are mean ± SD. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; n = 3. S11WT, psiCHECK-2 vector containing miR-103a-3p binding site 1; S11MT,
psiCHECK-2 vector containing mutant miR-103a-3p binding site 1.
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to induce observable functional effects (Karreth et al. 2011;
Tay et al. 2011; Ala et al. 2013). We focused on the first of
the two 5′ UTRMREs (i.e., site S11), which wasmore respon-
sive to miR-103a-3p/anti-miR-103a-3p treatment than the
site S12, and assessed the abilityof a sponge comprising 10 tan-
dem copies of the S11MRE to act as a decoy forGPRC5A. The
sponge vector was labeled GPRC5A-S11WTL (Supplemental
Fig. 4A,B), whereas the control sponge vector, which con-
tained 10 tandem copies of the mutant miR-103a-3p MRE,
was labeled GPRC5A-S11MTL (Supplemental Fig. 4C).
First, we verified that transfection of MIA PaCa-2 cells
with the true sponge GPRC5A-S11WTL reduced the expres-
sion level of the endogenous mature miR-103a-3p (19% ±
2.6%–P < 0.001) compared with transfection with the con-
trol sponge GPRC5A-S11MTL (Fig. 4A). More importantly,
transfection with the true sponge GPRC5A-S11WTL up-
regulated GPRC5A mRNA (data not shown) and to a larger
extent GPRC5A protein (Fig. 4B,C) compared with trans-
fection with the control GPRC5A-S11MTL. We were able to
recapitulate the sameobservations inHPNE, a second pancre-
as cell line: In HPNE cells, transfection with the GPRC5A-
S11WTL sponge up-regulated GPRC5A mRNA (61.6%–P <
0.001) and GPRC5A protein (56%–P < 0.01) compared
with transfection with the control sponge GPRC5A-
S11MTL (Supplemental Fig. 5A–C). We also tested with a lu-
ciferase reporter construct containing the second (S12WT) 5′
UTR binding site of miR-103a-3p and found that a single
copy of it suffices to up-regulate GPRC5A mRNA (23%–
P < 0.001)—see Supplemental Figure 5D.
We repeated the above experiments, this time cotransfect-
ingMIAPaCa-2 andHPNEcells with Pre-miR-103a-3p in ad-
dition to cotransfecting with GPRC5A-S11WTL or GPRC5A-
S11MTL. The level of miR-103a-3p decreased inMIA PaCa-2
cells that were cotransfected with GPRC5A-S11WTL by
43% ± 2.1% compared with cells cotransfected with control
GPRC5A-S11MTL (P < 0.001) (Fig. 4D). This translated to
an increase of both GPRC5A mRNA (P < 0.001) and protein
levels in MIA PaCa-2 and HPNE cells that were cotransfected
with Pre-miR-103a-3p and GPRC5A-S11WTL compared
with MIA PaCa-2 and HPNE cells cotransfected with Pre-
miR-103a-3p and control GPRC5A-S11MTL (Fig. 4E–G;
Supplemental Fig. 6A–C).
Lastly, we tested a third pancreas cell line (Panc-1) as well as
a nonpancreas one (HEK-293T) and were able to recapitulate
the above findings in both (Supplemental Fig. 7A–C). In par-
ticular, we transfected HEK-293T cell with the GPRC5A-
S11WTL and the control sponge GPRC5A-S11MTL: We
found that, just likewith theHPNE andMIAPaCa-2 cell lines,
GPRC5A-S11WTL up-regulated GPRC5A protein compared
with control, albeit somewhat modestly.
These experiments provide additional evidence that miR-
103a-3p regulates GPRC5A by directly interacting with the
latter’s 5′ UTR. Moreover, they demonstrate that GPRC5A’s
5′ UTR can potentially function as a decoy for other miR-
103a-3p targets.
DISCUSSION
The potential of miRNA regulation of mRNAs through bind-
ing sites that occur in 5′ UTRs was demonstrated early on
(Lytle et al. 2007;Moretti et al. 2010).However, only a few val-
idated examples of naturally occurring 5′ UTRmiRNA targets
exist in the literature to date (Jopling et al. 2005; Lytle et al.
2007; Orom et al. 2008; Lee et al. 2009; Grey et al. 2010;
Vora et al. 2013). For two of these few examples, the seed-
driven constitutive miRNA interaction with the 5′ UTR of
the targeted mRNA promoted protein translation and thus
led to an increase (instead of a decrease) of protein levels
(Orom et al. 2008; Tsai et al. 2009).
The described work and findings represent one more data
point in support of 5′ UTR targeting by endogenous miRNAs
whereby the targeting reduced the abundance of both the
mRNA and corresponding protein. In particular, using lucif-
erase assays, we provided initial evidence that the putative
MREs in the 5′ UTR of GPRC5A were in fact targeted by
FIGURE 3. MiR-103a-3p targeting of the 5′ UTR of GPRC5A mRNA
decreases GPRC5A protein level. (A) GPRC5A protein expression level
was determined byWestern blots in MIA PaCa-2 cells that were cotrans-
fected with a control vector containing GFP open frame region (OFR),
Pre-miR-scramble or Pre-miR-103a-3p, and either the GPRC5A-
5′UTR-CDS or the GPRC5A-CDS expression vector. (B) Quantifica-
tion result of A. (GFP) Green fluorescent protein is transfection control.
Actin is internal control. 5′UTR-CDS, pcDNA vector containing
GPRC5A 5′ UTR and CDS region; CDS, pcDNA vector containing
GPRC5A CDS region. All numerical data are mean ± SD. (∗∗∗) P <
0.001, n = 3.
5′ UTR targeting of GPRC5A mRNA
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FIGURE 4. Overexpression of the 5′ UTR MRE can increase GPRC5A mRNA and protein levels. (A) MiR-103a-3p expression is inhibited by over-
expression of the wild-type sponge (S11WTL) compared with the control sponge (S11MTL) in MIA PaCa-2 cells. (B) GPRC5A protein expression is
promoted by overexpression of wild-type miR-103a-3p binding site compared with the mutant site in MIA PaCa-2 cells. (C) Quantification result of
B. (D) Taqman miRNA assay was performed to test mature miR-103a-3p expression in MIA PaCa-2 cells cotransfected with pre-miR-103a-3p and
S11WTL. Cells cotransfected with pre-miR-103a-3p and S11MTL were used as controls. (E) GPRC5A mRNA expression was tested by RT-PCR in
MIA PaCa-2 cells treated with Pre-miR-103a-3p in addition to cotransfecting with GPRC5A-S11WTL or GPRC5A-S11MTL. (F) GPRC5A protein
expression was tested by Western blots in MIA PaCa-2 cells treated with Pre-miR-103a-3p in addition to cotransfecting with GPRC5A-S11WTL or
GPRC5A-S11MTL. (G) Quantification result of F. All numerical data are mean ± SD. (∗) P < 0.05; (∗∗∗) P < 0.001, n = 3. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase;GAPDH and Actin are internal controls. S11WTL, pcDNAvector containing 10 tandem copies of miR-103a-3p binding site
1; S11MTL, pcDNA vector containing 10 tandem copies of mutant miR-103a-3p binding site 1.
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miR-103a-3p. Additionally, we designed two constructs,
GPRC5A-5′UTR-CDS and GPRC5A-CDS, and demonstrat-
ed that GPRC5A-5′UTR-CDS, but not GPRC5A-CDS, re-
sponded to overexpression of miR-103a-3p, thereby further
supporting the finding that the miR-103a-3p MREs were lo-
cated in GPRC5A’s 5′ UTR. By overexpressing a sponge that
we constructed to contain 10 tandem copies of the most re-
sponsive (site S11) of the two 5′ UTR MREs we were able to
reduce the endogenous levels of miR-103a-3p and to up-reg-
ulate both GPRC5A mRNA and protein levels.
Wealsodemonstrated that the S115′UTRMREcould func-
tion as a decoy ofmiR-103a-3p in vitro and was able to reduce
miR-103a-3p levels and increaseGPRC5AmRNA and protein
levels. We established these findings in three pancreatic cell
lines: the normal epithelial HPNE cell line and the MIA
PaCa-2 and the Panc-1 cancer cell lines. These findings have
the following important ramification. MiR-103a-3p has been
shown to play important roles in cellular processes such as
DNArepair,metabolism,cell cycleprogression,andcelldiffer-
entiation (Liu et al. 2009; Yang et al. 2009; Finnerty et al. 2010;
Liao and Lonnerdal 2010; Polster et al. 2010) and to be dysre-
gulated inmultiplediseases (e.g., cancers) andconditions (e.g.,
diabetes, Alzheimer’s disease, etc.) (Roldo et al. 2006; Xie et al.
2009; Yao et al. 2010). To date only a few targets are known for
miR-103a-3p. In light of our decoying finding and givenmiR-
103a-3p’s involvement in so many settings it follows that
GPRC5A, through its 5′ UTR MRE for miR-103a-3p, could
potentially regulate indirectly processes such as DNA repair,
metabolism, the cell cycle, etc., by modulating the expression
of other mRNAs, in complete analogy to what was recently
shown for PTEN (Tay et al. 2011). When one considers that
in some cancers GPRC5A has been shown to act as an onco-
gene, whereas in others as a tumor suppressor, the potential
of GPRC5A to act through miR-103a-3p as a competing en-
dogenous RNA or ceRNA (Karreth et al. 2011; Tay et al.
2011; Ala et al. 2013) for other protein-coding transcripts sug-
gests thatGPRC5Amaybe involved inpreviouslyunsuspected,
currently uncharacterized, andpresumably complex genenet-
works. Studying these possible roles of GPRC5A is currently
the topic of ongoing research activity in our laboratory.
MATERIALS AND METHODS
Cell culture
The HEK-293T, MIA PaCa-2, HPNE, and Panc-1 cell lines were ob-
tained from the American Type Culture Collection. All of these cells
were grown in DMEM medium (Fisher Scientific) supplemented
with 10% fetal bovine serum (Life Technologies), 1% Penicillin
and Strep (Fisher Scientific), and 1% glutamine (Fisher Scientific),
at 37°C in a humidified atmosphere containing 5% CO2.
Cell transfection
The cells were transfected with 50 nM Pre-miR-103a-3p or 50 nM
Anti-miR-103a-3p (Ambion) by the reverse transfectionmethod us-
ing the X-tremeGENE siRNA transfection reagent (Roche). Cells
transfected with only a scrambled sequence, either Pre-miR-scram-
ble or Anti-miR-scramble (Ambion), were examined in parallel as
controls. Cells were then subjected to further assays or to RNA/pro-
tein extraction after 2 d. Lipofectamine 2000 (Life Technologies) was
used for transfection of the psiCHECK-2 reporter vector (Promega)
and pcDNA-3.1 overexpression vector (Life Technologies) and for
cotransfection of vectors and Pre-miRs.
RNA isolation and real-time quantitative polymerase
chain reaction analysis
Total RNA was extracted using TRIzol reagent (Life Technologies).
For the detection of GPRC5A mRNA, first-strand complementary
DNA was synthesized from 1000 ng of total RNA in the presence
of oligo-dT (12–18) primer (Promega) and MMLV reverse tran-
scriptase according to the manufacturer’s instructions (Promega).
Human glyceraldehyde 3-phosphate dehydrogenase RNA was am-
plified in parallel as an internal control. Real-time quantitative po-
lymerase chain reaction (qPCR) was performed with SYBR Green
PCR Master Mix (Life Technologies) and 20 ng of templates using
a StepOnePlus Real-Time PCR System (Life Technologies). For
miR-103a-3p detection, TaqMan MicroRNA Assay is performed
with themiR-103a-3p probe (Life Technologies) following theman-
ufacturer’s instructions. HumanU6 is used as internal control. Eight
nanograms of total RNA is used in the RT reaction with 5X RT
primers. All primer sequences used for GPRC5A mRNA and miR-
103a-3p detection are listed in Supplemental Table 1 (available on-
line). PCRs were performed at 95°C for 5 min, followed by 40 cycles
of 95°C for 15 sec and 60°C for 1 min. ΔCt was calculated by sub-
tracting the Ct of U6 or glyceraldehyde 3-phosphate dehydrogenase
mRNA from the Ct of the mRNA of interest. ΔΔCt was then calcu-
lated by subtracting the ΔCt of the negative control from the ΔCt of
the sample. The fold change in mRNA or miRNAwas calculated ac-
cording to the equation 2ΔΔCt.
Computational prediction of putative targets
Using the rna22 algorithm that we published previously (Miranda
et al. 2006) and that has been used by us and others to identify many
miRNA targets beyond the 3′ UTR of genes (Duursma et al. 2008;
Lal et al. 2008, 2009; Tay et al. 2008; Rigoutsos 2009; Marin-
Muller et al. 2013), we identified two candidate targets for miR-
103a-3p in GPRC5A’s mRNA. In what follows, we will be using
the terms “miRNA binding site” and “miRNA response element”
(MRE) interchangeably.
DNA vectors
The coding region of the GPRC5A mRNA with and without the 5′
UTR was amplified by PCR from MIA PaCa-2 cDNA. The DNA
sequence with 10 tandem repeats of the predicted miR-103a-3p
binding sites and the control DNA sequence with 10 tandem repeats
of seed-region mutant miR-103a-3p-binding sites were synthesized
as fragments (Life Technologies). The fragments were inserted into
the pcDNA-3.1 vector between the NheI and NotI sites. The vectors
were labeled GPRC5A-5′UTR-CDS, GPRC5A-CDS, GPRC5A-
S11WTL, and GPRC5A-S11MTL, respectively.
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Reporter vectors
The predicted microRNA binding sites or MREs for microRNA-re-
sponse element were synthesized as sense and antisense oligomers,
annealed, and cloned into a psiCHECK-2 vector. We created two
instances: one where the predictedmiRNA binding sites were cloned
into the psiCHECK-2 vector, directly 3′-downstream from, and a
second where they were cloned directly 5′-upstream of Renilla
Luciferase. These reporters were labeled S11WT-3′Luc, S11MT-
3′Luc, S11WT-5′Luc, and S11MT-5′Luc, S12WT-3′Luc, S12MT-
3′Luc, S12WT-5′Luc, and S12MT-5′Luc, respectively (WT: wild
type; MT: mutant). All primers used for these constructs are listed
in Supplemental Table 1.
Luciferase assay
Each psiCHECK-2 vector containing a reporter construct was
cotransfected into HPNE and MIA PaCa-2 cells with Pre-miR-
103a-3p or anti-miR-103a-3p by using Lipofectamine 2000 accord-
ing to the manufacturer’s protocol for cotransfection of DNA and
pre-miRs. In parallel, each psiCHECK-2 vector containing a report-
er construct was also cotransfected into HPNE and MIA PaCa-2
cells with pre-miR-scramble or Anti-miR-scramble as control.
Cells were harvested at 48 h after transfection, and the Renilla and
Firefly luciferase activities in the cellular lysate were assayed by using
the Dual-Glo Luciferase Assay (Promega) according to themanufac-
turer’s protocol. Light intensity for each sample wasmeasured by us-
ing Synergy 2 Multi-Mode Microplate Reader (BioTek), and each
value from Renilla luciferase was normalized by Firefly luciferase.
Western blots
Transfected cells were lysed on ice in Pierce IP lysis buffer (Thermo
Scientific) containing 1X complete protease inhibitor (Roche).
Debris was pelletized by centrifugation at 13,200 rpm for 15 min,
and protein concentrations were determined using Pierce BCA assay
(ThermoScientific). Lysateswereheat-denaturedat100°C for 10min
beforeseparation in10%sodiumdodecyl sulfate–polyacrylamidegels
and transferred to nitrocellulose membrane (GE Healthcare).
Membranes were blocked with 5% bovine serum albumin (Sigma-
Aldrich) in Tris-buffered saline Tween-20 buffer (10 mM Tris at
pH7.6, 150mMNaCl, and0.1%Tween-20) andprobedwithprimary
antibody in Tris-buffered saline Tween-20 with 5% bovine serum
albumin at the recommended dilutions at 4°C. Primary antibodies
included GPRC5A antibody (Sigma-Aldrich), β-actin antibody
(Cell Signaling Technology), and GFP antibody (Santa Cruz Biotech-
nology Inc.). Membranes were incubated with secondary antibody
(Cell Signaling Technology) diluted in Tris-buffered saline Tween-20
with5%bovineserumalbuminfor1hat roomtemperature.The signal
was detected with Pierce ECL Western Blotting Substrate (Thermo
Scientific) and GE ImageQuant LAS 4000 (GE Healthcare).
Statistical analysis
Statistical analysis was performed using Excel (Microsoft) and SPSS
(IBM). Unless otherwise indicated, the level of significance for the
difference between data sets was assessed using one-way analysis
of variance. Data are expressed as the means ± SD. P-values ≤0.05
were considered statistically significant.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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